Array Biopharma (ARRY) Reports In-Line Q1 EPS

Array Biopharma (NASDAQ: ARRY) reported Q1 EPS of ($0.22), in-line with the analyst estimate of ($0.22). Revenue for the quarter came in at $29.7 million versus the consensus estimate of $33.28 million.

For earnings history and earnings-related data on Array Biopharma (ARRY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15